In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...